News about "Sun Pharma "

Sun Pharma Reports Q1FY27 Results

Sun Pharma reported a 10.1 percent YoY rise in Q1 FY27 sales to INR 151,836 million, while net profit increased to INR 28,948 million, driven by strong business growth.

Sun Pharma | 01/08/2026 | By News Bureau |  101

Sun Pharma Acknowledges Organon Shareholder Approval for Acquisition

Sun Pharma has acknowledged Organon shareholders' approval of the proposed acquisition, marking a key milestone toward completion of the transaction.

Sun Pharma | 24/07/2026 | By News Bureau |  175

Sun Pharma Receives Approval to Manufacture and Market Generic Semaglutide in South Africa

Sun Pharma has received approval to manufacture and market generic semaglutide in South Africa, available as a once-weekly pre-filled multi-dose injectable pen in 2 strengths.

Sun Pharma | 15/07/2026 | By News Bureau

Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal

Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.

Sun Pharma | 22/06/2026 | By News Bureau

Alembic Pharma Names Ramesh Juneja as EVP, Human Health

Alembic Pharmaceuticals has appointed Ramesh Juneja as Executive Vice President–Human Health for its India business. Bringing leadership experience from Sun Pharma, Cipla and Reliance Retail, Juneja will spearhead sales and marketing initiatives to drive growth in Alembic’s domestic pharmaceutical business.

Sun Pharma | 02/06/2026 | By News Bureau |  127

Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity

Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.

Sun Pharma | 21/03/2026 | By News Bureau |  753

Sun Pharma Announces US FDA Acceptance of sBLA Application for ILUMYA to Treat Adults with Active Psoriatic Arthritis

The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.

Sun Pharma | 17/03/2026 | By News Bureau |  180

MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).

Sun Pharma | 13/03/2026 | By News Bureau |  141

Sun Pharma to Invest Rs 500 Crore in Expansion of Assam Manufacturing Unit

Sun Pharmaceutical Industries said it will invest Rs 500 crore to expand its manufacturing facility in Assam, aiming to strengthen its domestic production infrastructure and support future growth.

Sun Pharma | 06/02/2026 | By Darshana |  229

Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection

Sun Pharmaceutical has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management, paving the way for its entry into the fast-growing obesity treatment segment once the semaglutide patent expires in the country.

Sun Pharma | 27/01/2026 | By News Bureau |  273